Navigation Links
Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
Date:9/4/2007

PHILADELPHIA, Pa., Sept. 4 /PRNewswire-FirstCall/ -- GlaxoSmithKline (NYSE: GSK) today announced new results from a large study that demonstrate combination treatment with AVODART (dutasteride) and the alpha blocker tamsulosin provides significantly greater urinary symptom improvement for men with enlarged prostate than either AVODART or tamsulosin monotherapy over 24 months. Three analyses from the study - Combination therapy with Avodart and tamsulosin (CombAT) - were presented today at the 29th annual meeting of the Societe Internationale d'Urologie in Paris.

In addition, one of three analyses presented -- a post hoc analysis -- showed that AVODART provides a pattern of increasing enlarged prostate symptom improvement over 24 months. Tamsulosin -- the most commonly prescribed medicine for the condition -- provided early symptom improvement, but this improvement plateaued from month three through 24.1 Common symptoms of enlarged prostate include nocturia, frequency and urgency, incomplete emptying, starting and stopping, and weak stream.

The CombAT study includes 4,800 men (combination therapy, n=1492; AVODART, n=1502; tamsulosin, n=1519) with moderate-to-severe enlarged prostate symptoms. All study participants received placebo for four weeks and then were randomized to receive AVODART and tamsulosin combination therapy, AVODART monotherapy, or tamsulosin monotherapy.

Enlarged prostate (also known as benign prostatic hyperplasia (BPH)), is a condition that affects 50 percent of men over the age of 50 and more than 90 percent of men over age 80. AVODART belongs to a class of medicines known as 5 alpha reductase inhibitors (5 ARIs), which shrink the prostate over time. Tamsulosin is an alpha blocker,
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2007 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... , June 18, 2013 Remedy Informatics, ... healthcare and life sciences research, today announced it ... (GSA) IT Schedule 70 supply contract (GS-35F-367AA, effective ... provide innovative IT solutions to government agencies at ... this contract, Remedy has placed its products and ...
(Date:6/18/2013)...  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ), the ... a general corporate update in conjunction with its 2013 Annual ... at 2:10 p.m. Pacific Time in Carlsbad, CA. ... as follows: 2:00 p.m. – 2:10 p.m. Annual Meeting of ... 2013) 2:10 p.m. – 3:15 p.m. Corporate Presentation – ...
(Date:6/17/2013)... 2013  Hanger, Inc. (NYSE:  HGR) today announced the ... its senior secured facilities to an aggregate of up ... credit agreement includes a $200 million revolving credit facility ... credit agreement was comprised of a $100 million revolving ... new facility matures on June 17, 2018, and is ...
Breaking Medicine Technology:Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 2Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 3Remedy Informatics Awarded GSA Contract to Provide Innovative IT Solutions to Federal, State and Local Agencies 4Isis Pharmaceuticals to Present a General Corporate Update at its 2013 Annual Meeting of Stockholders and Open House 2Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities 2Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities 3
(Date:6/18/2013)... Pomona, Calif. (PRWEB) June 18, 2013 ... associate professor of Family Medicine for the College of ... of Health Sciences has been elected president of the ... Gov. Edmund G. Brown Jr. appointed Connett, a 1984 ... , OMBC members recently elected Connett to the position ...
(Date:6/18/2013)... Lauren Sciences, a privately-held biotechnology company furthering development ... today that it was independently recognized as a ... Platform, and selected as a Featured Company, in ... , The report, " Early Stage Drug Delivery ... features companies MCD Group independently selected as technology ...
(Date:6/18/2013)... Center enrolled their first patients in the ROADSTER Study, ... procedure to help clear blockages in carotid arteries and ... people in the United States are diagnosed with blockages, ... these blockages can slow or even stop blood flow ... known as a "brain attack." , Current treatment ...
(Date:6/18/2013)... are scrambling to gather data for the FDA to ... brain injury in the United States. The University of ... in the Journal of Neurotrauma that it ... instead of one., Jeffrey J. Bazarian, M.D., M.P.H., an ... the first to show that measuring a combination of ...
(Date:6/18/2013)... The world,s first computer guided fitness training system ... of the three winners of the LeWeb,13 London ... , The startup company, Genetrainer, building on ... PhD graduate, Ralph Pethica and Julian Gough, Professor ... Science, was selected from over 350 startups to ...
Breaking Medicine News(10 mins):Health News:UH Case Medical Center among first to enroll patients for global carotid artery trial 2
... Salamon HealthDay Reporter , TUESDAY, Aug. 2 (HealthDay ... but there may be a way to shorten its misery: ... in certain formulations may cut the length of colds by ... the University of Helsinki in Finland, reviewed 13 placebo-controlled trials ...
... (GSA) the nation,s largest interdisciplinary organization devoted to ... of the College of St. Scholastica as the 2011 ... Gerontology Outstanding Mentorship Award. This distinguished honor is ... commitment and dedication to mentoring minority researchers in the ...
... the nation,s largest interdisciplinary organization devoted to the field ... Boston University as the 2011 recipient of the Excellence ... honor is given annually to acknowledge outstanding contributions in ... in any or all of the areas of teaching ...
... (GSA) the nation,s largest interdisciplinary organization devoted to ... Dixit, DVM, PhD, of the Pennington Biomedical Research Center ... Investigator Award. The distinguished honor is given for ... biological research. It was established in 1986 to honor ...
... used to determine whether a lung cancer patient is ... in the August issue of the Journal of ... International Association for the Study of Lung Cancer (IASLC). ... found to respond well to crizotinib, an ALK inhibitor ...
... , TUESDAY, Aug. 2 (HealthDay News) -- Americans used to ... the case, according to a new study that gives high-income ... in particular, and obesity are to blame, said the U.S. ... expectancy in coming years and help to reduce health care ...
Cached Medicine News:Health News:Larger Dose of Zinc Lozenges May Shorten Colds 2Health News:Mehrotra to receive GSA's 2011 Minority Mentorship Award 2Health News:Jette to receive GSA's 2011 Excellence in Rehabilitation of Aging Persons Award 2Health News:Dixit to receive GSA's 2011 Nathan Shock New Investigator Award 2Health News:Americans No Longer Outliving Europeans: Study 2
Sphincter of Oddi Solid State Catheter Adapter Cable for Polygraf ID...
... diagnosis of influenza A and ... due to the availability of ... of influenza using Clearview Exact ... lead to reduced hospital stays, ...
... A1c-Cellular is the first HbA1c control available ... the entire HbA1c procedure including the lysing ... is a ready-to-use liquid control with an ... closed-vial stability of six months when refrigerated. ...
...
Medicine Products: